Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Sydney X. Lu et al.|JAMA Oncology|2021Cited by 119
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaOla Landgren, Ingemar Turesson, Jonathan N. Hofmann et al.|JAMA Oncology|2019Cited by 97
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95
Non-viral vectors for chimeric antigen receptor immunotherapySandy Tretbar, Ulrich Blache, Joel G. Rurik et al.|Nature Reviews Methods Primers|2024Cited by 12